Cgm Dexcom denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Dexcom CGM as Duplicate Therapy

A "duplicate therapy" denial from UnitedHealthcare (UHC) means their system flagged an existing active claim or covered benefit for glucose monitoring — typically a fingerstick blood glucose meter and supplies — and determined that CGM duplicates that benefit. This is almost always an administrative determination, not a clinical one. UHC's review process may not have accounted for the clinically distinct function of continuous monitoring versus periodic fingerstick checks, or there may be a billing overlap that can be resolved at the claim level.

## Why This Denial Is Appealable

A duplicate-therapy denial can be challenged on two tracks. First, if the denial rests on a coding or billing overlap, a corrected resubmission by your provider may resolve it without a formal appeal. Second, if UHC maintains that CGM is functionally duplicative, that is a substantive determination subject to full appeal rights under ACA §2719 (for non-grandfathered plans) and ERISA §503 (for employer-sponsored plans). You have approximately 180 days from the denial to file your first internal appeal and approximately four months from the final internal denial to request independent external review. Expedited review is available when a delay would seriously jeopardize your health.

## The Appeal Process

1. Clarify the basis of the duplicate determination. Request UHC's written explanation of which existing benefit the Dexcom CGM allegedly duplicates and which clinical criteria were applied. 2. Coordinate with your provider to confirm that claims were submitted under the correct and distinct HCPCS codes for CGM versus conventional blood glucose monitoring. 3. File a Level 1 internal appeal with documentation establishing that CGM and conventional fingerstick monitoring are clinically distinct modalities serving different clinical functions. 4. Escalate to external review if internal appeals are exhausted.

## Documentation to Gather

• Prescriber letter: Your physician should articulate the clinical distinction between CGM and conventional monitoring for your specific case — the continuous data stream, trend arrows, and alert features that conventional monitoring cannot provide — and explain why both are not duplicative for your management plan.
• FDA labeling for Dexcom: The approved labeling describes the device's function; this anchors the clinical-distinction argument.
• Current monitoring records: Documentation of any existing glucose monitoring regimen and its limitations for your case.
• Diagnosis and clinical complexity documentation: Chart notes supporting the medical need for continuous monitoring.

## Criteria-Mapping Structure

Obtain UHC's coverage policy and duplicate-therapy criteria. For each criterion cited, provide specific documentation. The core argument in a duplicate-therapy appeal is clinical distinction: demonstrate concretely, from the chart and from the FDA labeling, that the Dexcom CGM provides clinical information that the "duplicate" benefit cannot, and that your prescriber determined this distinction is clinically necessary for your care.